evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

25 questions · 27 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 4 · 14.8%GRADE not reported 0 · 0%Very low 12 · 44.4%Low 9 · 33.3%Moderate 2 · 7.4%High 0 · 0%

Infliximab 5–10 mg/kg vs placebo

Clinical remission defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5–10 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with placebo (very low certainty).

1 finding from 1 review

Infliximab 5–10 mg/kg vs placebo

Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5–10 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with placebo (very low certainty).

1 finding from 1 review

Infliximab 5 mg/kg and purine analogues vs purine analogues

Clinical response as defined by the studies at week 26 · Patients with active Crohn's disease

Infliximab 5 mg/kg and purine analogues probably leads to higher clinical response as defined by the studies at week 26 compared with purine analogues alone (moderate certainty).

1 finding from 1 review